19-Feb-2026
No headlines found.
Compugen to Participate in Upcoming Investor Conferences
PRNewswire (Thu, 19-Feb 7:00 AM ET)
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
PRNewswire (Tue, 17-Feb 7:00 AM ET)
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
PRNewswire (Thu, 12-Feb 7:00 AM ET)
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
PRNewswire (Wed, 17-Dec 7:00 AM ET)
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
Compugen Ltd. - trades on the NASDAQ stock market under the symbol CGEN.
As of February 19, 2026, CGEN stock price climbed to $1.79 with 235,984 million shares trading.
CGEN has a beta of 1.02, meaning it tends to be more sensitive to market movements. CGEN has a correlation of 0.08 to the broad based SPY ETF.
CGEN has a market cap of $167.39 million. This is considered a Micro Cap stock.
Last quarter Compugen Ltd. - reported $2 million in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-778,598 and exceeded earnings estimates by $.02.
In the last 3 years, CGEN traded as high as $3.03 and as low as $.53.
The top ETF exchange traded funds that CGEN belongs to (by Net Assets): SPDW, GWX.
CGEN has underperformed the market in the last year with a return of -19.7%, while SPY returned +12.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CGEN shares. However, CGEN has outperformed the market in the last 3 month and 2 week periods, returning +11.9% and +12.6%, while SPY returned +3.6% and +1.0%, respectively. This indicates CGEN has been having a stronger performance recently.
CGEN support price is $1.64 and resistance is $1.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEN shares will trade within this expected range on the day.
